Breakthrough in Personalized Medicine: Novel Assay for Enhanced Molecular Profiling and CNS Monitoring

Researchers from the Molecular Genetics Laboratory have developed a novel assay that simultaneously detects mutations, immunoglobulin (IG) fusions, and IG V(D)J clonality in plasma and cerebrospinal fluid (CSF) to enhance molecular profiling and CNS monitoring in diffuse large B-cell lymphoma (DLBCL) patients. This non-invasive approach offers improved sensitivity for CNS surveillance and potential to inform personalized treatment strategies.

Key Takeaways:

• The novel assay detects mutations, IG fusions, and IG V(D)J clonality in 100%, 72.2%, and 78.6% of plasma ctDNA samples, respectively.
• The incorporation of IG fusion detection enabled molecular subtyping without requiring FISH.
• Plasma ctDNA analysis identified additional mutations absent in tumor tissue, reflecting clonal heterogeneity.
• The assay revealed genomic alterations in 8 cases in CSF, while conventional imaging and cytology confirmed CNS involvement in only 3.
• This ctDNA assay offers a non-invasive, integrated approach for genomic profiling and disease monitoring in DLBCL.
• The study concluded that this approach has the potential to inform personalized treatment strategies.
• **Accurate detection:** The novel assay detects mutations, IG fusions, and IG V(D)J clonality in 100%, 72.2%, and 78.6% of plasma ctDNA samples, respectively.
• **Improved sensitivity:** The assay revealed genomic alterations in 8 cases in CSF, while conventional imaging and cytology confirmed CNS involvement in only 3.
• **Non-invasive approach:** The ctDNA assay offers a non-invasive, integrated approach for genomic profiling and disease monitoring in DLBCL.
• **Potential for personalized medicine:** This approach has the potential to inform personalized treatment strategies for DLBCL patients.